David Einhorn Cassava Sciences Inc Transaction History

Greenlight Capital Inc

  • $1.97 Billion
  • Q4 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$32.6 - $53.05 $1.32 Million - $2.15 Million
-40,620 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$36.77 - $90.91 $1.49 Million - $3.69 Million
40,620 New
40,620 $1.78 Million

Others Institutions Holding SAVA

# of Institutions
207
Shares Held
14M
Call Options Held
2.98M
Put Options Held
6.57M
View Full List

About CASSAVA SCIENCES INC

SAVA Quotes by TradingView
  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $94.2M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track David Einhorn's Portfolio

Track David Einhorn Portfolio

Follow David Einhorn (Greenlight Capital Inc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenlight Capital Inc, based on Form 13F filings with the SEC.

News

Stay updated on Greenlight Capital Inc and David Einhorn with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email